<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04969679</url>
  </required_header>
  <id_info>
    <org_study_id>MUTAUC01</org_study_id>
    <nct_id>NCT04969679</nct_id>
  </id_info>
  <brief_title>Additive Effect of Probiotics (Mutaflor®) in Patients With Ulcerative Colitis on 5-ASA Treatment.</brief_title>
  <official_title>A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effect of Mutaflor in Patients With Mild-to-moderate Ulcerative Colitis on 5-ASA Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kangbuk Samsung Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kangbuk Samsung Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      E.coli Nissle 1917 (Mutaflor®) is equivalent to mesalazine in preventing disease relapse in&#xD;
      ulcerative colitis. However, data on ability of E.coli Nissle 1917 (Mutaflor®) to induce&#xD;
      remission compared with placebo is limited. Investigators aim to investigate the efficacy of&#xD;
      E.coli Nissle 1917 (Mutaflor®) as an add-on treatment to 5-ASA in mild to moderate ulcerative&#xD;
      colitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicentre, double-blind, randomised, placebo-controlled study in patients with&#xD;
      mild-to-moderate UC.&#xD;
&#xD;
      Subjects were randomly assigned to receive either E.coli Nissle 1917 (Mutaflor®) or placebo&#xD;
      once daily for 8 weeks, and inflammatory bowel disease questionnaire (IBDQ) scores, clinical&#xD;
      remission, and response rate were compared.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 16, 2018</start_date>
  <completion_date type="Actual">June 3, 2020</completion_date>
  <primary_completion_date type="Actual">June 3, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare and evaluate the increase in IBDQ(Inflammatory bowel disease questionnaire) score between the Mutaflor group and the Placebo group</measure>
    <time_frame>8weeks</time_frame>
    <description>The evaluation of the beneficial effects of Mutaflor on mild-to-moderate UC patients, was assessed by an increase in the IBDQ score more than 16 points from baseline to week 8.&#xD;
The Score can range from 32 to 224, with higher scores reflecting better HRQOL(Health-related quality of life)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the clinical remission between Mutaflor group and Placebo group</measure>
    <time_frame>4weeks, 8weeks</time_frame>
    <description>Partial Mayo≤1, assessed at week 4 or Mayo≤2, assessed at week 8. Mayo score can range from 0-12 with higher scores indicating worse severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the clinical response between Mutaflor group and Placebo group</measure>
    <time_frame>4weeks, 8weeks</time_frame>
    <description>Partial Mayo≤2 or decrease more than 2 points, assessed at week 4 or Mayo≤ 2 or decrease more than 2 points, assessed at week 8.&#xD;
Mayo score can range from 0-12 with higher scores indicating worse severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in endoscopic scores between Mutaflor group and Placebo group</measure>
    <time_frame>8weeks</time_frame>
    <description>Assessed by the endoscopic subgroup score=0 of the mayo. Mayo Endoscopic Sub Scores can range from 0-3, with higher scores indicating worse severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the endoscopic response between Mutaflor group and Placebo group</measure>
    <time_frame>8weeks</time_frame>
    <description>Assessed by the endoscopic subgroup score=0 or decrease more than 1 point. Mayo Endoscopic Sub Scores can range from 0-3 with higher scores indicating worse severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Microbiome(stool) change between Mutaflor group and Placebo group</measure>
    <time_frame>8weeks</time_frame>
    <description>Stool microbial change including diversity. DNA extraction from stool samples and 16S rRNA gene sequencing analysis. calculating α- and β-diversities.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>E. coli Nissle 1917 (Mutaflor®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active group will receive E. coli Nissle 1917 (Mutaflor®).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo group will receive placebo drug.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E. coli Nissle 1917 (Mutaflor®)</intervention_name>
    <description>Take 1 capsule per day in the morning from the first day to the fourth day and take 2 capsules per day from the fifth day to the end of the testing period.(for 8 weeks)</description>
    <arm_group_label>E. coli Nissle 1917 (Mutaflor®)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Take 1 capsule per day in the morning from the first day to the fourth day and take 2 capsules per day from the fifth day to the end of the testing period.(for 8 weeks)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ulcerative colitis patients over the age of 19 with mild to moderate symptoms using&#xD;
             5-ASA (Mayo score 3-9)&#xD;
&#xD;
          -  Patient who signed the consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The extent of ulcerative colitis is limited to proctitis&#xD;
&#xD;
          -  History of bowel resection&#xD;
&#xD;
          -  History of using other medication than 5-ASA such as immunomodulators, steroid or&#xD;
             biologics within 3months&#xD;
&#xD;
          -  history of using antibiotics or probiotics within 2 weeks&#xD;
&#xD;
          -  Pregnant or lactating woman&#xD;
&#xD;
          -  Requiring hospitalization and imminent need for surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Soo-kyung Park</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 7, 2021</study_first_submitted>
  <study_first_submitted_qc>July 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kangbuk Samsung Hospital</investigator_affiliation>
    <investigator_full_name>Soo-kyung Park</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Mutaflor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

